CAS CAS Pharmacology & Medication-Assisted Treatment 2

Question 1

Under the DATA 2000 waiver (now updated by the SUPPORT Act), which providers were originally authorized to prescribe buprenorphine for OUD in office-based settings?

Accepted Answer

Physicians who obtained a DEA X-waiver after completing required training

Answer

DATA 2000 established the DEA X-waiver system allowing qualifying physicians to prescribe buprenorphine for OUD after completing required training hours, later expanded to nurse practitioners and physician assistants.

Question 2

Medication-Assisted Treatment (MAT) is best defined as the use of FDA-approved medications combined with:

Accepted Answer

Counseling and behavioral therapies to provide a whole-patient approach

Answer

SAMHSA defines MAT as a combination of FDA-approved medications with counseling and behavioral therapies, recognizing that medication alone is insufficient for long-term recovery.

Question 3

A client on methadone maintenance asks why they cannot receive take-home doses after one week. The CAS should explain that take-home doses are granted based on:

Accepted Answer

Federal regulations that require demonstrated stability and time in treatment before take-home privileges are granted

Answer

Federal regulations (42 CFR Part 8) establish specific criteria—including time in treatment, urine drug screen results, and behavioral stability—that must be met before take-home doses are permitted.

Question 4

Opioid-induced precipitated withdrawal can occur when buprenorphine is administered while full opioid agonists are still occupying receptors because:

Accepted Answer

Buprenorphine displaces full agonists from receptors but only partially activates them, causing abrupt withdrawal

Answer

Because buprenorphine has high receptor affinity, it displaces full agonists but produces only partial activation, causing sudden, severe withdrawal if given too soon after the last full agonist dose.

Question 5

Which of the following is a primary advantage of extended-release injectable naltrexone (Vivitrol) over oral naltrexone for OUD?

Accepted Answer

It eliminates adherence problems associated with daily oral dosing

Answer

Extended-release injectable naltrexone is administered monthly by a clinician, eliminating the daily adherence challenge that frequently leads to oral naltrexone discontinuation.

(CAS) Certified Addiction Specialist Practice Test

(CAS) Certified Addiction Specialist Practice Test

CAS CAS Pharmacology & Medication-Assisted Treatment 2